Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Promore Pharma Regains Rights for PXL01 Manufacturing

STOCKHOLM, SWEDEN, February 15, 2018 –  Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that it will assume responsibility for the manufacturing of the investigational medicinal product for the clinical Phase III trial for PXL01 and at the same time, the company regains the global manufacturing rights for the commercial product.In March 2016, Promore Pharma entered into an agreement with PharmaResearch Products Ltd ("PRP") regarding development collaboration on PXL01, complemented by a manufacturing agreement in January 2017. In accordance

Dow BioMedica to distribute Biohit GastroPanel® in Korea

Biohit Oyj Press release, 15[th] February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1[st] quarter of 2018. CEO Young Gill Shin, Dow BioMedica Inc.: “Korea has high incidence of Helicobacter pylori infection caused atrophic gastritis and related risks such as gastric cancer. GastroPanel as a primary examination will find patients for further examination, and allows more cost-

Selumetinib in NF1 gets FDA orphan drug status

15 February 2018 07:00 GMT SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE US FDA FOR NEUROFIBROMATOSIS TYPE 1 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 births,[i]  with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and

Aspire Global Year-end report 2017

A strong fourth quarter led to record numbers in both revenue and EBITDA for the full year 2017Fourth quarter (Oct-Dec 2017) · Revenues increased by 27% to MEUR 19.2 (15.1) · B2B Revenues increased by 40% to MEUR 10.3 (7.3) · EBITDA increased by 35% to MEUR 3.8 (2.8) · EBITDA margin increased to 20% (19%) · EBIT increased by 33% to MEUR 3.5 (2.6) · Earnings after tax amounted to MEUR 3.3 (3.7) · Basic earnings per share*, after tax, from continued   operations amounted to EUR 0.03 (0.09) · First Time Depositors (FTDs) increased by 55% to 68.0 thousand (43.8)

REG Power Management Selects Greenbyte for Data Management

REG Power Management has selected Greenbyte’s modern software systems Breeze for wind farm management and Bright for solar PV plant management.REG Power Management, headquartered in Guildford UK, is a developer, owner and operator of renewable energy projects, with a track record of over 1000 MW. Greenbyte will work with REG Power Management to bring into Breeze and Bright their current portfolio of 30 wind farms and 10 solar PV plants. The systems will be used for real time production monitoring, streamlined reporting and in-depth data analysis over any time period to optimize plant energy

Bank of Lithuania issues inspection findings on Swedbank

During autumn 2017, the Bank of Lithuania has carried out an inspection related to Swedbank’s activities in the area of money laundering and terrorism financing prevention (AML/CTF) for the period January 2016 until March 2017.The findings include deficiencies in internal control systems for money laundering prevention, processes and documentation. Based on the results, Bank of Lithuania issued a warning to Swedbank and obliged to remedy identified deficiencies. -Swedbank takes the findings by Bank of Lithuania very seriously. We would like to emphasize that AML and CTF is a prioritised

Attendo's year-end report 2017 - New record in the number of new nursing homes, the Board has appointed Pertti Karjalainen as acting CEO

Attendo showed a record high number of new beds in nursing homes being established during 2017. Profit for the fourth quarter was in line with the same quarter 2016, but at a lower margin. The number of units under construction remains at a very high level and is laying a foundation for continued stable growth.Comments by Henrik Borelius, CEO “With a record high number of establishments and acquisitions, Attendo sharply increased the number of beds in own operations during the year. At year-end 2017, Attendo had 13,262 beds in own operations, an increase by 43 percent compared to

Clavister Q4 2017: All-time High Quarter and Full Year Revenues

Clavister’s Q4 2017 report shows record revenues and gross profit. Q4 revenues grew to 27% and reached 34.4 MSEK. The full year growth was 28%, reaching all-time annual revenues  over 100 MSEK.February 15, 2018. Örnsköldsvik, Sweden. Clavister (Nasdaq: CLAV), a leader in high-performance network security solutions, released its latest quarterly report showing increases in key metrics including Q4 revenues reaching 34,4 MSEK(+27%), gross margin rose to 77%, and gross profit improved by 31%, year-on-year.For the full year 2017, the revenues rose by 28% and reached, for the first time, over

Summons to the Annual General Meeting of shareholders in Castellum AB (publ)

The shareholders of Castellum AB (publ), Reg. No. 556475-5550, are hereby summoned to the Annual General Meeting to be held on Thursday, March 22, 2018 at 5 pm in RunAn, Chalmers Kårhus, Chalmersplatsen 1, Gothenburg. The entrance opens at 4 pm.Notification etc.Shareholders wishing to attend the Annual General Meeting must be registered as shareholders in the share register kept by Euroclear Sweden AB by Friday, March 16, 2018 and must also have notified their attendance to the company no later than Friday, March 16, 2018 (preferably before 4 pm). Notification of attendance at the

Year-end report January-December 2017

The fourth quarter developed positively for Bong. Stable envelope sales and qrowth in light packaging compared to previous year contributed to a continued improvement in earnings. The milestone of a positive result before tax for the full year was achieved. The cash flow was also strong and this allows for continued investments in light packaging to accelerate Bongs transformation, says Bong’s CEO Håkan Gunnarsson.October – December 2017• Net sales amounted to SEK 578 million (579)• Operating profit before depreciation increased to SEK 29 million (28)• Operating profit increased to

Hexagon announces next generation Leica Rugby lasers – the first upgradable lasers for construction

Hexagon, a leading global provider of information technology solutions, launched today the Leica Rugby CLH and Leica Rugby CLA lasers. This next generation of lasers offer the unique capability to adapt to user application needs through software upgrades – an industry first.With a focus on application flexibility, simplicity and durability, the new Leica Rugby lasers increase productivity and allow for maximum performance as construction projects evolve.These new lasers provide users access to upgrades that extend functionality and adapt to application needs. This ensures users have the

Elos Medtech builds up a strong platform within Dental Implant Systems

Elos Medtech announces that Soren Olesen, Managing Director of Elos Medtech Pinol, will take up a new role as Dental Business Director and lead our global dental implant strategy within one of our important business segments, Dental Implant System. During the years Elos Medtech has evolved a strong global dental offering as development- and manufacturing partner. Specialized expertise within development and manufacturing as well as innovative developed dental instruments and digital dentistry products, is the platform for Elos Medtech’s dental strategy and future growth. Elos Medtech has

Immunovia Full Year report, January-December 2017

“The fourth quarter of 2017 marked an important inflection point for Immunovia in many aspects. We ended our final year of purely pre-commercial activity, and have now started what is planned as our first business year that will lead to the start of sales in the second half of 2018.” “During 2018 we expect to reach our target of starting commercial sales of IMMray™  PanCan –dby providing the test to customers, both private individuals and health organizations, so-calledself-pay customers.” “The internal work aimed at preparing the company for a listing on Nasdaq Stockholm’s main market

Year-end report 2017

Quarter 4, 2017  · Incoming orders amounted to SEK 815.9m (830.5), which organically is a decrease of 0.8 percent compared with the same period last year. · Net sales amounted to SEK 860.0m (820.1), which organically is an increase of 4.9 percent compared with the same period last year. · Adjusted operating profit was SEK 106.8m (85.5), giving an adjusted operating margin of 12.4 percent (10.4). · Operating profit was SEK 99.1m (85.5), giving an operating margin of 11.5 percent (10.4). · Net profit was SEK 73.2m (61.1). · Earnings per share were SEK 6,26 (5,23).

IES will not receive central government subsidy for homework support for the calendar year 2018

The Swedish National Agency for Education has decided that Internationella Engelska Skolan i Sverige Holdings II AB (“Internationella Engelska Skolan” or “IES”) (through its subsidiary Internationella Engelska Skolan i Sverige AB as principal) will not receive central government subsidy for homework support for the calendar year 2018. In the application to the Swedish National Agency for Education, IES had applied for homework support for 42,925 teaching hours for 23,264 students calendar year 2018. In June 2017, IES received 21 MSEK in central government subsidy for homework support for

Notice of Annual General Meeting

Gothenburg, 15 February 2018: Notice is hereby given that the Annual General Meeting of Aktiebolaget SKF will be held at SKF Kristinedal, Byfogdegatan 4, Gothenburg, Sweden, at 13.00 on Tuesday, 27 March 2018. The doors are open from 11.00. Refreshments will be served prior to the Annual General Meeting between 11.00 and 12.30. Annual General Meeting For the right to participate at the meeting, shareholders must be recorded in the shareholders' register kept by Euroclear Sweden AB by Wednesday, 21 March 2018 and must notify the company at the latest on the same day by letter to

TC TECH recruits Björn Hallare as COO with focus on product development, quality assurance and manufacturing

TC TECH Sweden AB (publ) announces that Björn Hallare has been appointed as the company’s chief operating officer (COO) after having served as interim COO since the autumn of 2017. Björn’s 25 years of experience from managing development and industrialization projects at companies such as Ericsson, Huawei and Telia add important knowledge to the company’s development of production systems for light guide plates (LGPs) used in LCD displays.During his time as interim COO, Björn Hallare was highly instrumental in the development of the company’s new version of the production system for high-

Starbreeze AB (publ) Year-end Report 2017

Today at 10.00 am CET, Starbreeze CEO Bo Andersson Klint and CFO Sebastian Ahlskog will host a live stream and present the report on Starbreeze Twitch channel: https://www.twitch.tv/starbreeze FOURTH QUARTER 2017 · Net sales increased by 4.4 percent to SEK 103.8 million (99.4). · PAYDAY generated SEK 20.4 million (37.8) and Dead by Daylight accounted for SEK 67.6 million (54.6) of net sales. · EBITDA amounted to SEK 6.4 million (38.8). · The loss before tax amounted to SEK -67.9 million (32.3). · Basic and diluted earnings per share were SEK -0.22 (0.11). · New

Starbreeze decides on previously announced rights issue of approximately SEK 150 million

THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, UNITED STATES, OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD NOT COMPLY WITH OR REQUIRE REGISTRATION UNDER APPLICABLE LAWS AND REGULATIONS. STOCKHOLM (15 February 2018) The Board of Directors of Starbreeze AB (publ) (“Starbreeze” or the “Company”) has decided on a rights issue of approximately SEK 150 million before issuing

Notice of extraordinary general meeting in Starbreeze AB (publ)

STOCKHOLM (15 February, 2018) The shareholders in Starbreeze AB (publ) reg. no. 556551-8932 (the “Company”) are hereby convened to the extraordinary general meeting on Tuesday 20 March 2018, at 10.30 at Carnegie Investment Bank AB with address Regeringsgatan 56, 103 38 Stockholm. Notice etc. Shareholders who wish to participate at the extraordinary general meeting shall: · be registered in the share register kept by Euroclear Sweden AB on Wednesday 14 March 2018, and · notify the Company no later than Thursday 15 March 2018, preferably before 16.00, to address Starbreeze AB,

Interim Report October-December 2017: Stable production and strong demand enhance competitiveness

LKAB continued to demonstrate stable production and delivery volumes during the last quarter of 2017 and demand for LKAB’s highly upgraded iron ore products remained strong. For the full year, LKAB is reporting increased volumes, improved earnings and stronger cash flow compared with previous year.“Continued increased volumes in combination with a higher iron ore price and strong demand for our highly upgraded, climate-efficient products have enhanced our competitiveness during the year,” says LKAB’s President and CEO Jan Moström. Strong fourth quarterLKAB is reporting a strong fourth

Stora Enso introduces augmented reality app for Multicopy Zero paper

STORA ENSO OYJ PRESS RELEASE 15 February 2018 at 9 EET Stora Enso has created an Augmented Reality (AR) mobile app for its carbon-neutral office paper product Multicopy Zero, a product in Stora Enso’s flagship paper brand family, Multicopy.The Multicopy Zero AR app lets the user explore the product in the forest where it comes from, as augmented reality overlays virtual information on the natural environment. The forest comes to life as the app enables the user to experience an elk walking through the forest, chanterelles on the ground and birds flying and chirping in the air. The AR app

Tokmanni Group Corporation: Notification of Manager’s Transactions

Tokmanni Group Corporation                  Stock exchange release      15 february at   9:00 (EECT)Person subject to the notification requirement Name:                                     Harri Sivula Position:                                 Member of the Board Notification Type:                     Initial Notification Reference number:                  743700VMG6KWF0FW1560_20180214162645_3 ____________________________________________________________________ Issuer Name:                                     Tokmanni Group Corporation LEI:

There are no items matching the current filter
There are no more items matching the current filter
Back to top